• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Freeman Kevin D bought $27,000 worth of shares (10,000 units at $2.70), increasing direct ownership by 18% to 33,469 units (SEC Form 4)

    10/16/24 4:12:20 PM ET
    $GALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GALT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    FREEMAN KEVIN D

    (Last) (First) (Middle)
    C/O GALECTIN THERAPEUTICS INC.
    4960 PEACHTREE INDUSTRIAL BLVD., STE 240

    (Street)
    NORCROSS GA 30071

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GALECTIN THERAPEUTICS INC [ GALT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/16/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/16/2024 P 5,000 A $2.7 33,469 D
    Common Stock 10/16/2024 P 5,000 A $2.7 80,000 I By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC(1)
    Common Stock 18,063 I IRA
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
    Jack W. Callicutt, by power of attorney 10/16/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GALT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GALT

    DatePrice TargetRatingAnalyst
    6/17/2025$6.00Buy
    H.C. Wainwright
    More analyst ratings

    $GALT
    SEC Filings

    See more
    • Galectin Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

      8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)

      7/9/25 7:55:45 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galectin Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)

      6/16/25 12:01:06 PM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galectin Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GALECTIN THERAPEUTICS INC (0001133416) (Filer)

      5/15/25 7:55:30 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GALT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026

      NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, announced today it entered into a new $10 million unsecured line of credit facility with Richard E. Uihlein, Chairman of Galectin Board of Directors, and its largest individual stockholder. "Belapectin has the potential to address a significant unmet medical need in MASH cirrhosis, and I am committed to ensuring that the Company is funded sufficiently in order to fully evaluate the potential of its MASH cirrhosis program," said Richard

      7/9/25 8:00:00 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

      6/18/25 11:19:00 AM ET
      $CATX
      $CGON
      $GALT
      $ONCY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

      NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include: Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance K

      6/10/25 8:56:08 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shlevin Harold H. bought $7,540 worth of shares (6,500 units at $1.16), increasing direct ownership by 75% to 15,206 units (SEC Form 4)

      4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

      12/31/24 7:45:05 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zordani Richard A. Jr. bought $8,164 worth of shares (10,000 units at $0.82), increasing direct ownership by 31% to 42,083 units (SEC Form 4)

      4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

      12/26/24 8:16:12 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Eldred Kary bought $11,045 worth of shares (13,469 units at $0.82), increasing direct ownership by 27% to 63,682 units (SEC Form 4)

      4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

      12/26/24 8:07:55 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Czirr James C gifted 20,000 shares, acquired $6,000 worth of shares (1,000 units at $6.00) and exercised 323,125 shares at a strike of $2.16, increasing direct ownership by 41% to 1,045,541 units (SEC Form 4)

      4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

      6/11/25 6:25:16 PM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Czirr James C acquired $12,000 worth of shares (2,000 units at $6.00) and gifted 23,200 shares, decreasing direct ownership by 3% to 741,416 units (SEC Form 5)

      5 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

      6/11/25 5:18:21 PM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Lewis Joel gave a grant of 56,420 shares, decreasing direct ownership by 6% to 832,592 units (SEC Form 4)

      4 - GALECTIN THERAPEUTICS INC (0001133416) (Issuer)

      3/5/25 4:00:26 PM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Galectin Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Galectin Therapeutics with a rating of Buy and set a new price target of $6.00

      6/17/25 7:49:59 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Galectin Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Galectin Therapeutics with a rating of Buy and set a new price target of $14.00 from $12.00 previously

      4/16/21 7:35:20 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GALT
    Leadership Updates

    Live Leadership Updates

    See more
    • Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

      6/18/25 11:19:00 AM ET
      $CATX
      $CGON
      $GALT
      $ONCY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

      NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in March 2024 as Vice President Clinical Development and Medical Director, Khurram has quickly integrated himself into our team and has led the management of our NAVIGATE clinical trial of belapectin

      8/1/24 8:00:00 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

      NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. "We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program" said Pol F. Boudes, M.D., Chief Medical Officer. "His breadth of expertise in clinical development, especially in hepatology and liver cirrhosis, along with his experience with regulatory interactions a

      3/12/24 8:00:00 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GALT
    Financials

    Live finance-specific insights

    See more
    • Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update

      NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated "This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last week at the European Association for the Study of the Liver (EASL), specifically that we successfully demonstrated a clinically significant response in a key biomarker (Fibroscan®) that is used to

      5/15/25 8:00:00 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

      NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "In the U.S. approximately 5 million adults are affected by MASH cirrhosis and clinically significant portal hypertension. The need for new treatments that can prevent disease progression is more urgent than anticipated. The NAVIGATE trial's per-protocol analysis in U.S. patients revealed a remarkable 68% reduction i

      3/31/25 8:00:00 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

      NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin in patients with MASH cirrhosis. As we eagerly await the topline results next month, we remain hopeful that belapectin may be a potential new treatment for the large number of patients in the U.S.

      11/14/24 8:00:00 AM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $GALT
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • SEC Form SC 13D/A filed by Galectin Therapeutics Inc. (Amendment)

      SC 13D/A - GALECTIN THERAPEUTICS INC (0001133416) (Subject)

      12/1/23 4:38:34 PM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insider Analysis: Purchase at Galectin Therapeutics Inc. on Jun 20

      Recently, on June 20, 2024, Galectin Therapeutics Inc. saw an insider purchase by Director Freeman Kevin D. He bought $5,950 worth of shares, which amounted to 2,500 units at a price of $2.38 per share. This transaction increased his direct ownership by 10% to 28,469 units, as reported in the SEC Form 4. It's essential to analyze this insider purchase in the context of previous transactions within the company. On February 7, 2024, Uihlein Richard E was granted 23,256 shares, increasing his direct ownership by 0.23% to 10,268,751 units. Similarly, on the same date, Zordani Richard A. Jr. filed an SEC Form 4. Continuing the trend, a new insider, Carson Benjamin Sr, filed an SEC Form 3 on Febr

      6/20/24 6:44:03 PM ET
      $GALT
      Biotechnology: Pharmaceutical Preparations
      Health Care